The multiplexed diagnostic assay is used to identify multiple analytes in a single run cycle. Multiplex assay is used in the detection of defects such as mutation in functional biomolecules (DNA, mRNA, and protein) with the help of DNA microarray, multiplex PCR, and next-generation sequencing. In multiplexed diagnostic market, multiplexed diagnostic assay is executed in research & diagnostic laboratories, hospitals, and drug development. Moreover, this multiplexed diagnostic tool is also used in the diagnosis of various diseases, infections, drug screening, and biomarkers.
The multiplexed diagnostic market is gaining significant traction due to rising prevalence of autoimmune diseases. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of arthritis from 2013 to 2015 was 54 million in the U.S. adults (22.7%) and by 2040, it is expected to reach 78 million (26%) in the U.S. adults of age 18 years or above. The data represent high prevalence of autoimmune diseases, indicating the need of advance diagnostic measures, which is expected to boost growth of the multiplexed diagnostic market over the forecast period.
- This report provides in-depth analysis of the global multiplexed diagnostic market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global multiplexed diagnostic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Luminex Corporation, Thermo Fisher, Illumine Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Abbott Laboratories, Siemens Healthineers, Agilent technologies, BioMerieux SA, and F.Hoffmann-La Roche Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, product type up-gradation, market expansion, and marketing tactics
- The global multiplexed diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiplexed diagnostic market
-
- Reagents & Consumables
- Instruments
-
- Disease Diagnostics
- Molecular Diagnostics
- Drug Development
-
- Hospitals
- Clinical Laboratories
- Academic & Research Institutes
- Others
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Luminex Corporation
- Thermo Fisher
- Illumine Inc.
- Bio-Rad Laboratories, Inc.
- Qiagen N.V.
- Abbott Laboratories
- Siemens Healthineers
- Agilent technologies
- BioMerieux SA
- Hoffmann-La Roche Ltd.
